Wellness company Medifast (NYSE: MED) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, but sales fell by 36.9% year on year to $75.1 million. On the other hand, next quarter’s revenue guidance of $72.5 million was less impressive, coming in 15.2% below analysts’ estimates. Its GAAP loss of $1.65 per share was significantly below analysts’ consensus estimates.

Is now the time to buy MED? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Medifast’s fourth quarter results outperformed Wall Street’s revenue expectations, which the market responded to positively. Management attributed this to early signs of success from its transition to a metabolic health-focused business model and improvements in coach productivity. CEO Dan Chard highlighted that this was the first quarter since mid-2022 where coach productivity turned positive year-over-year, up 6%. Chard noted, “These early performance metrics are yet to have appreciable impact on our revenue, but they are nonetheless early signs of the improving performance of our coaches.”

Medifast’s forward-looking guidance is shaped by its ongoing transformation and new product development aimed at addressing metabolic health beyond weight loss. Management expects new offerings leveraging its metabolic synchronization science to address needs of both new and returning clients, with particular focus on individuals coming off GLP-1 medications. President Nick Johnson stated, “Our optimal metabolic health story and the science behind it is giving coaches a sharper focus and stronger confidence in delivering meaningful value to their clients.”

Key Insights from Management’s Remarks

Management attributed Q4’s relative outperformance to the company’s sharpened focus on metabolic health, coach productivity improvements, and early operational discipline.

• Leadership transition announced: CEO Dan Chard will step down in June 2026, with President Nick Johnson set to succeed him. Chard will remain as Chairman and emphasized the planned nature of this transition to ensure business continuity.
• Coach productivity turnaround: For the first time since mid-2022, coach productivity increased year-over-year, driven by enhanced training and a renewed focus on the metabolic health story rather than traditional weight loss. Management views this as a leading indicator for potential future growth.
• Metabolic health strategy implemented: The company launched its “metabolic synchronization” approach, moving beyond weight loss to address broader metabolic dysfunction. This included a clinically supported system that targets improvements in body composition, energy, and overall health.
• Operational restructuring and cost discipline: Medifast executed a company-wide restructuring, reducing marketing expenses and realigning staff to better match lower revenue levels. Management expects over $30 million in targeted future savings from these actions.
• New product pipeline development: The company is developing a proprietary product line to reduce visceral fat and improve metabolic efficiency, aiming to launch in late 2026. Management believes these innovations will help reinforce Medifast’s repositioning in the growing metabolic health market.

Drivers of Future Performance

Medifast’s outlook is anchored in new product launches, continued coach productivity gains, and cost control as it pursues growth in the evolving metabolic health market.

• Product innovation and launches: Management expects the upcoming metabolic health product line to drive renewed client engagement, especially among individuals transitioning off GLP-1 medications. The focus is on clinically proven outcomes, such as visceral fat reduction and lean mass preservation.
• Coach base revitalization: The evolving coach demographic—with a higher proportion of newer, more productive coaches—is expected to sustain momentum in client acquisition and retention. Management believes this shift will create a “flywheel” effect, historically linked to business stabilization and eventual growth.
• Cost discipline and operational flexibility: The company plans to maintain tight cost controls, leveraging its restructured operations to fund strategic investments in research and product development. Management warns that benefits from these changes may take several quarters to fully materialize.

Catalysts in Upcoming Quarters

Looking ahead, StockStory analysts will focus on (1) the launch and uptake of Medifast’s new metabolic health product line, (2) sustained improvements in coach productivity and the mix of newer, more engaged coaches, and (3) ongoing progress in cost reduction and operational restructuring. The successful execution of these initiatives will be key to assessing whether Medifast can return to growth and profitability.

Medifast currently trades at $10.98, up from $10.76 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

Stocks That Trumped Tariffs

If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.

Don’t wait for the next volatility shock. Check out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.